JP Morgan Initiates Coverage On Kailera Therapeutics with Overweight Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 50.5%

Neg 0% Neu 0% Pos 50.5%

JP Morgan analyst Hardik Parikh initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Overweight rating and announces Price Target of $30.